- Home
- SBT vs TRVI Comparison
SBT vs TRVI Comparison
Compare SBT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBT
- TRVI
- Stock Information
- Founded
- SBT 1984
- TRVI 2011
- Country
- SBT United States
- TRVI United States
- Employees
- SBT N/A
- TRVI N/A
- Industry
- SBT Savings Institutions
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SBT Finance
- TRVI Health Care
- Exchange
- SBT Nasdaq
- TRVI Nasdaq
- Market Cap
- SBT 253.2M
- TRVI 211.4M
- IPO Year
- SBT 2017
- TRVI 2019
- Fundamental
- Price
- SBT $4.86
- TRVI $4.65
- Analyst Decision
- SBT
- TRVI Strong Buy
- Analyst Count
- SBT 0
- TRVI 8
- Target Price
- SBT N/A
- TRVI $9.31
- AVG Volume (30 Days)
- SBT 25.6K
- TRVI 4.0M
- Earning Date
- SBT 01-22-2025
- TRVI 11-06-2024
- Dividend Yield
- SBT N/A
- TRVI N/A
- EPS Growth
- SBT N/A
- TRVI N/A
- EPS
- SBT 0.12
- TRVI N/A
- Revenue
- SBT $67,988,000.00
- TRVI N/A
- Revenue This Year
- SBT N/A
- TRVI N/A
- Revenue Next Year
- SBT $6.68
- TRVI N/A
- P/E Ratio
- SBT $40.95
- TRVI N/A
- Revenue Growth
- SBT N/A
- TRVI N/A
- 52 Week Low
- SBT $4.40
- TRVI $1.26
- 52 Week High
- SBT $5.97
- TRVI $4.60
- Technical
- Relative Strength Index (RSI)
- SBT 55.96
- TRVI 75.02
- Support Level
- SBT $4.81
- TRVI $2.36
- Resistance Level
- SBT $4.86
- TRVI $4.60
- Average True Range (ATR)
- SBT 0.03
- TRVI 0.33
- MACD
- SBT -0.00
- TRVI 0.21
- Stochastic Oscillator
- SBT 57.14
- TRVI 92.46
About SBT Sterling Bancorp Inc.
Sterling Bancorp Inc is a unitary thrift holding company. Its primary business is the operation of its wholly-owned subsidiary, Sterling Bank, through which it offers a range of loan products to the residential and commercial markets, as well as retail banking services. The products and services offered by the bank include saving and current accounts, demand and term deposits, payment cards, trade finance, fund transfer, treasury and cash management. It provides services such as construction loans, residential real estate, commercial real estate, commercial lines of credit and other consumer loans.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.